The United Kingdom and the United States have hammered out a major commercial pact that will guarantee zero levies on British drug shipments going into the US market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has committed to raise funding on pharmaceuticals through the NHS. This pledge secures that import taxes on these vital goods will remain at nothing for a timeframe of the next three years.
This development comes after recent threats to dramatically increase tariffs on patented pharmaceutical imports, with increases floated reaching one hundred percent.
"This arrangement with the Britain strengthens the international landscape for innovative medicines and introduces much-needed fairness to American-British drug exports," an announcement noted.
Commercial Importance
Drugs constitute one of the Britain's biggest export categories to the United States, which is easily the primary buyer for major companies like GSK and AstraZeneca.
Statistics show that in the year leading up to last September, the UK shipped medicines totaling £11.1bn to the US. This figure represented a significant portion of British export trade in that period.
"This agreement protects work, increases capital expenditure and paves the way for the UK to emerge as a worldwide center for biotech and pharma," a minister commented.
Key British Pledges
The deal involves several specific changes from the British government:
- Price Threshold Increase: The UK will increase the price threshold at which it judges new treatments to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a aim to double total public funding on drugs from 0.3% of Gross Domestic Product to 0.6% over the coming ten years.
- Rebate Cap: The sum pharmaceutical firms must refund to the NHS to prevent overspending will be capped at 15%. In the past, refunds exceeded 20%.
Recent Tensions
The pact takes place against a long-running row between the pharmaceutical industry and the UK government over spending levels and NHS adoption.
These tensions were exacerbated by claims that American patients were paying a premium for the equivalent treatments than consumers in the Britain and the EU.
Over the last 18 months, several large manufacturing plans in the UK have been paused or scrapped, while major expansions have been announced toward American operations.
A senior figure publicly accepted that the NHS must invest a greater share on treatments, noting that its expenditure on drugs had decreased as a percentage of its resources over the previous ten-year period.
